BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Transgene and NEC Report Sustained Disease-Free Survival With TG4050 in Head and Neck Cancer at ASCO 2025

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (...

June 03, 2025 | News

Kexing Biopharm’s GB18 Receives IND Approval in China and U.S. for Cancer Cachexia Treatment

Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) applica...

May 30, 2025 | News

China Approves First Homegrown ADC, Trastuzumab Rezetecan, for HER2-Mutant Lung Cancer

The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically develo...

May 30, 2025 | News

Daiichi Sankyo Launches ENDEAVOUR Program to Empower Emerging Lung Cancer Experts and Advance Collaborative Research

ENDEAVOUR unites 21 promising lung cancer specialists with internationally recognized experts to foster collaboration and improve patient outcomes Thr...

May 26, 2025 | News

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

May 21, 2025 | News

Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer

Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...

May 19, 2025 | News

Agilent and Ubix Therapeutics Join Forces to Advance Targeted Cancer Therapies in South Korea

Research focuses on targeted protein degradation and antibody-drug conjugate as promising modalities for developing next-generation cancer therapies ...

May 15, 2025 | News

Hyundai ADM Bio Withdraws IND for Penetrium™/Docetaxel and Pivots to Immunotherapy Combinations

Hyundai ADM Bio announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Pene...

May 14, 2025 | News

EnGeneIC Doses First Patient in Phase I/IIa Trial for EGFR-Positive Solid Tumours at Mater Hospital, Sydney

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North Sydney Recruitment to open this month at Frankston Hospital, ...

May 13, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

May 12, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...

May 05, 2025 | News

TAE Life Sciences and Ohio State Forge Landmark BNCT Partnership to Advance Next-Generation Boron-Based Cancer Therapies

TAE Life Sciences (TLS) announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center – ...

May 05, 2025 | News

Stay Connected